Today: 29 June 2026
Reckitt share price slips at London open as tariff jitters set the tone
23 February 2026
1 min read

Reckitt share price slips at London open as tariff jitters set the tone

London, Feb 23, 2026, 08:23 GMT — Regular session

Reckitt Benckiser Group plc (RKT.L) slipped 0.1% to 6,410 pence early Monday in London, with shares opening at 6,430 pence and fluctuating between 6,378 and 6,430 pence, LSE.co.uk’s delayed figures show. The FTSE 100 consumer goods company, priced around 30 times earnings, is still hovering near its 52-week high.

The stock barely budged, with markets jittery to start the week as U.S. tariff developments rattled futures and left investors cautious. “The tariff landscape is now more uncertain than before,” said Rodrigo Catril, senior FX strategist at NAB, as FTSE futures slipped. Reuters

Reckitt’s shares have surged heading into late February, so investors are scanning for the next catalyst, debating whether to stick around or pull some money out. In markets like this, staples sometimes offer a safe haven—until that stops being the case.

The company’s been tweaking its portfolio and handing cash back to investors, moves that have kept shareholders engaged and left the stock quick to react to shifts in positioning. Reckitt wrapped up the sale of its Essential Home business on Dec. 31 and has put forward a plan for a special dividend alongside a share consolidation.

The company’s share consolidation, a move that shrinks the share count and lifts the per-share price to reflect the large cash payout, kicked in on Feb. 2. According to the company, ordinary shares outstanding stand at 674,005,752, out of which 29,252,346 are sitting in treasury. That leaves 644,753,406 voting rights in total.

Now that work is mostly wrapped, attention returns to how Reckitt is actually performing. Investors are watching: can Health and Hygiene volumes hold up without over-relying on price hikes? And if brand support ramps, margins come into question.

Investors are set to scrutinize management’s comments on cash use following the portfolio reset. The focus: potential for additional buybacks, pace of debt reduction, and what the company now considers bolt-on M&A, especially with market prices no longer low.

The risks aren’t exactly hidden. Margins can shrink fast if emerging-market demand slips, promotions ramp up, or currencies swing harder. Tariff chatter, too, can chill consumer sentiment, “defensive” sector or not.

Reckitt’s next big event comes March 5, with full-year results and an investor presentation scheduled for 08:30 GMT at the London Stock Exchange.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • US Stocks Rise as Megacaps Offset Small Cap Declines; Comcast Soars on NBCUniversal Spin-off
    June 29, 2026, 12:47 PM EDT. U.S. stocks edged higher Monday with gains led by megacap tech and consumer internet giants. The S&P 500 and Nasdaq proxies rose while the Russell 2000 small-cap index dropped over 1%. Semiconductor stocks lagged, reflecting a split in the AI-driven trade. Shares of Comcast (NASDAQ:CMCSA) surged 9.26% on news of a planned spin-off of NBCUniversal and Sky into an independent, tax-free company expected within a year. Industry watchers highlighted the narrow rally's risk, with increasing equity financing costs posing challenges. Despite broader caution, investors focused on large-cap names amid geopolitical developments and economic uncertainties.
Johnson & Johnson stock falls on DePuy sale talk — what to watch next for JNJ shares
Previous Story

Johnson & Johnson stock falls on DePuy sale talk — what to watch next for JNJ shares

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Next Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Go toTop